ABSTRACT -Antiemetic effects of serotonin 5-HT3 receptor antagonists (ICS205-930, zacopride, BRL43694, GR38032F) were investigated in Suncus murinus. Veratrine, nicotine, copper sulfate, cisplatin, cyclophosphamide and motion sickness were used as emetic stimuli. Serotonin 5-HT3 receptor antagonists did not inhibit emetic responses to veratrine, nicotine, copper sulfate and motion sickness. However, cisplatinand cyclophosphamide-induced emesis was strongly blocked by them. Both subcutaneous and intravenous injections of 5-HT3 antagonists were effective. Serotonin 5-HT, and 5-HT2 receptor antagonists were less effective. These results clearly indicate that a 5-HT3 receptor-mediated mechanism(s) is involved in the emesis caused by cancer chemotherapeutic agents and that 5-HT3 receptor antagonists are very effective as prophylactic drugs.
Nausea and vomiting are the major subjective side-effects of cancer chemotherapy, causing serious discomfort to the patients (1) . It has been reported that several 5-HT3 receptor antagonists such as MDL7222, ICS205-930, and zacopride inhibit emesis induced by cancer chemotherapeutic agents in the dog and ferret (2) (3) (4) . However, the precise mechanisms of the emesis caused by antitumor drugs is still not clear. Suncus murinus (a house musk shrew), used in this study, is a species of insectivora, which is considered to be closer to primates than rodents, lagomorphs and carnivores in the phylogenetic system (5) . We have shown previously that the Suncus murinus vomits in response to various drugs including cancer chemotherapeutics and motion stimulus and that the animal is suitable for research on antiemetic drugs (6) (7) (8) .
In the present study, the antiemetic effects of four 5-HT3 receptor antagonists (ICS205-930, zacopride, BRL43694, GR38032F) against several emetic stimuli (veratrine, nicotine, copper sulfate, cisplatin and cyclophosphamide) were studied and compared with those of 5-HT, and 5-HT2 antagonists.
MATERIALS AND METHODS
Experiments were performed on healthy adult Suncus murinus of either sex weighing 50-70g (male) and 30-50g (female). The animals, originally introduced from the Central Institute for Experimental Animals (Kanagawa, Japan), were bred in a temperaturecontrolled room at 24 ± 10C at the The Animal Care Institute of The University of Tokyo. They were allowed free access to pellet chow, supplied by the Central Institute for Experimental Animals, and tap water.
Experimental conditions were similar to those reported from our laboratory (6, 7) . Emetic stimuli employed were subcutaneous injection of copper sulfate (CuSO4: 40 mg/kg), nicotine (10 mg/kg), and veratrine (0.5 mg/kg); intravenous injection of cisplatin (40 mg/kg) and cyclophosphamide (200 mg/kg); and motion. An indwelling catheter was used for intravenous injection (see below). When the motion stimulus (frequency: 1 Hz, amplitude: 40 mm, duration: 5 min) was applied, each animal was placed in a transparent cage (5w x 15L X 12H cm) fixed on a reciprocal shaker (TAITEC R-30 mini, Taiyo Scientific Industrial Co., Ltd., Japan). After a 5-min equilibration period, the motion stimulus was started. The number of vomiting episodes and the latency to the first vomiting were recorded for 5 min (motion), 30 min (copper sulfate, nicotine, veratrine), or 90 min (cisplatin, cyclophosphamide).
Cisplatin and cyclophosphamide were toxic, and the suncus died within a week. Therefore, the animals injected with chemotherapeutics were killed after the experiment. Both male and female animals were used because there was no apparent sex difference. However, a more detailed experiment is currently ongoing.
The four 5-HT3 receptor antagonists (ICS205-930, zacopride, BRL43694, GR38032F) were subcutaneously injected to the animal 30 min prior to the emetic stimuli except cancer chemotherapeutic agents. In the case of cisplatin and cyclophosphamide, 5-HT3 receptor antagonists were injected intravenously. We also studied the effects of subcutaneous injection of ICS205-930 against intraperitoneally injected cisplatin-induced emesis. The dose of 5-HT3 receptor antagonists was started from 1 mg/kg, and changed with a factor of 2. The ID50 value of the antiemetic effect was determined by Brownlee's up-and-down method. Antiemetic effects of pindolol (5-HT1A antagonist), mianserin (5-HT1c and 5-HT2 antagonist) and ketanserin (5-HT2 antagonist) against cisplatin were also studied. A chronic jugular catheter was indwelt for the intravenous administration of 5-HT3 antagonists according to the method of Florczyk and Schurig (9) with a modification. The suncus was anesthetized with ether, and the fur on the ventral and dorsal area of the neck was clipped and swabbed with 70% alcohol. A single incision of about 1 cm was made with scissors on the ventral portion of the neck, and the left jugular vein was identified. A piece of 7-cm long polyethylene tubing (0.28 mm, I.D. by 0.61 mm, O.D., PE 10, Clay Adams, Parsippany, NJ, U.S.A) was heat flared at 1 cm from one end and heat bent at 2 cm from the same end. A small incision of about 5 mm was made on dorsal portion of the neck. Using a trochar, the catheter was guided from the ventral incision to the nape under the skin. The catheter was filled with 200 U/ml of sodium heparin, and a small stainless bar was used to seal the nape-side end. Then the catheter was inserted into the jugular vein and ligated together with the flare. The incision was closed using surgical glue which can set instantaneously. When the drugs were administered, 15 cm of polyethylene tubing was connected to the catheter, and the drug solution was injected into the animals without restraint. In some experiments, the emetic effects of copper sulfate (40 mg/kg, p.o.), nicotine (10 mg/kg, s.c.) or veratrine (0.5 mg/kg, s.c.) were studied using the catheter-indwelt animals, and we confirmed that the chronic implantation did not significantly affect vomiting responses of the animal.
The compounds except for cisplatin were dissolved in saline. The volume of drug solution injected was adjusted to 0.1 ml/50 g body weight except for cisplatin (i.v., 1.0 ml/50 g, i.p., 0.5 ml/50 g) and cyclophosphamide (0.5 ml/50 g). In the case of cisplatin, at first, the pH of the saline was adjusted to 4.0 using 0.1 N HCl, and the saline was warmed to about 50°C. Cisplatin was dissolved with this saline in the final concentration of 2 mg/ml, and the solution was cooled to 37°C just before the administration.
RESULTS
Copper sulfate, nicotine, and veratrine caused vomiting within 15 min and motion did within 2 min. However, cisplatin and cyclophosphamide caused emesis with a longe latency. Figure 1 shows the relationship be tween the time after the injection of cisplatii and cyclophosphamide and the averaged num ber of vomiting episodes for every 5 min There is a striking difference in the time course of the number of vomiting episodes be tween the two drugs. Cisplatin caused emesi with a longer latency, and the emesis occurrec periodically or not continuously. However, the emesis caused by cyclophosphamide was tran sient and completed within 30 min. Table 1 shows the effect of 5-HT3 recepto antagonists against several emetic stimuli. The drugs up to 64 mg/kg had no effect against the emesis induced by copper sulfate, nicotine, veratrine and motion. However, 5-HT3 antag-I onists strongly inhibited the cancer chemotherapeutics-induced emesis. (Table 2 ). We could not study the emetogenic effect of GR38032F because of its poor solubility. The maximum dose of GR38032F tested, 4 mg/kg, did not cause emesis. The severity of emesis of the drugs was apparently parallel to the potency of the antiemetic effects. At doses of less than 16 mg/kg, 5-HT3 receptor antagonists induced no extraordinary behavior in the animal.
Since 5-HT3 receptor antagonists were injected intravenously when antiemetic effects against cancer chemotherapeutics were studied, it is possible that the preventive effects depend on the route of administration. Therefore, effects of subcutaneously injected 5-HT3 antagonists were also studied. Emetic effects of cisplatin did not depend on the route of administration (M. Mutoh et al., submitted); The latency and number of vomiting episodes were virtually the same between intravenous and intraperitoneal injection. Therefore, intraperitoneal injection of cancer chemotherapeutics was employed in the following experiment. Subcutaneous injection of ICS205-930 also inhibited the emesis induced by intraperitoneal administration of 20 mg/kg cisplatin and 200 mg/kg cyclophosphamide with the ID50 value of 25 and 73 ,ug/kg, respectively. Table 3 depicts the effects of 5-HT1 and 5-HT2 receptor antagonists. Subcutaneous injection of pindolol, mianserin and ketanserin inhibited the emesis caused by intraperitoneal injection of cisplatin with ID50 values of 11.3, 6.9 and 4.0 mg/kg, respectively. However, pindolol induced excitation in the suncus, and spontaneous movement was increased when a dose higher than 16 mg/kg was administered. ID50 values were determined using the up-and-down method. -: no prevention of vomiting at doses up to 64 mg/kg, except for GR38032F which was up to 4 mg/kg. NT: not tested. Motion stimulus: reciprocal shaking on the horizontal plane (frequency 1 Hz, duration 5 min, amplitude 40 mm). Serotonin 5-HT3 antagonists were injected intravenously except that ICS205-930 was injected subcutaneously against intraperitoneal injection of cisplatin and cyclophosphamide. Values are the mean ± S.E.M., except for zacopride in which actual values are indicated. The drugs were injected subcutaneously. At a dose of 32 mg/kg, no emetic response was observed. Mianserin ( > 8 mg/kg) and ketanserin (> 4 mg/kg) caused sedative effects.
DISCUSSION
The existence of several subtypes of 5-HT receptors in a variety of tissue is well known, and recent introduction of highly selective 5-HT3 antagonists made it possible to study the role of 5-HT3 receptors more precisely (see 10). Serotonin 5-HT3 receptors were initially thought to exist solely in the peripheral nervous system, but recent studies suggest their existence in central nervous system (11) .
In the present study 5-HT3 receptor antagonists selectively inhibited the emesis induced by cancer chemotherapeutic agents in Suncus murinus. The results are consistent with those using other animals, i.e., dog, ferret and cat (2) (3) (4) 12) . A clinical study also showed the effectiveness of 5-HT3 antagonists (13) . Antagonists for 5-HT1 and 5-HT2 receptor blocked the emesis induced by cisplatin (Table 2 ), but about 40 to 100 times higher dose was necessary to show the antiemetic effect compared to 5-HT3 antagonists. Side effects were significant with these high doses. Therefore, it is clear that a 5-HT3 receptor-mediated mechanism(s) is involved in cancer chemotherapeutics-induced emesis. Although antiemetic effects of 5-HT3 receptor antagonists were reported from several laboratories, this is the first report to compare several antagonists using the same experimental procedure. Furthermore, our data showed that subcutaneous injection of 5-HT3 antagonists was as effective as intravenous injection.
High doses of ICS205-930, zacopride and BRL43694 were emetogenic themselves. Sancilio et al. (14) reported that orally administered zacopride induced emesis in ferrets. These data indicate that the 5-HT3 receptor antagonists currently available are partial agonists.
At present, we do not know the exact mechanism of the antiemetic effects of 5-HT3 receptor antagonists. The existence of 5-HT3 receptors in peripheral sensory nervous system is reported (15) . Cisplatin-induced emesis was completely inhibited by abdominal vagotomy, indicating that the drug stimulates vagus afferent (M. Mutoh et al., submitted). The 5-HT3 antagonists blocked only cisplatin-and cyclophosphamide-induced emesis. These results may indicate that the site of action for 5-HT3 antagonists is peripheral. However, it is suggested that 5-HT3 antagonists interact with mesolimbic dopaminergic systems (16) . Matsuki et al. (17) showed that SCH23390, a selective D1-antagonist, and YM-09151-2, a selective D2-antagonist, inhibited cisplatin-induced emesis but that dopamine antagonists also blocked the emesis induced by copper sulfate or motion. Therefore, interaction with the central dopaminergic nervous system is also plausible. Further experiments are necessary to clarify the emetic effects of cisplatin and the site of action for 5-HT3 antagonists.
There was a considerable difference between the emetic profiles induced by cisplatin and cyclophosphamide. Cyclophosphamide caused transient emesis, while cisplatin induced long-lasting emesis with long latency. Since ICS205-930 effectively blocked both types of emesis, a common mechanism seems to be exist. Injection of serotonin itself caused instantaneous emesis in the suncus (Y. Torn et al., unpublished observation). Therefore, the different patterns of emesis may reflect a difference in releasing serotonin rather than a different mechanism of emesis.
In conclusion, the present study indicates that 1) a 5-HT3 receptor-mediated mechanism(s) is involved in the emesis caused by cytotoxic drugs, 2) 5-HT3 antagonists are very effective as prophylactic drugs and 3) the suncus is a useful experimental animal for the development of antiemetic drugs.
